Sivelestat sodium alleviates sepsis-associated acute lung injury by inhibiting ferroptosis via the Nrf2/SLC7A11/GPX4 axis

14 Jul 20264 min read0 viewsJournal Feed

GIST (Key Takeaways)

by Ying Wang, Xiaoling Xia, Yan Lu, ChengLiang Zhang, Yaqing Zhou, Jingjing Fan Objective This study was aimed to investigate the therapeutic efficacy and mechanism of Sivelestat sodium in sepsis-associated acute lung injury (SALI). Methods A rat model of SALI was established using the cecal ligation and puncture (CLP) procedure.
After the model was established in rats, behavioral changes, abdominal conditions, and survival rates were monitored. Comparative analyses included arterial blood gas parameters, the lung wet/dry weight ratio (W/D), lung injury scores, histopathological damage assessment, inflammatory cytokine levels, oxidative stress marker levels, and Fe 2+ concentrations in lung tissue.
The expression levels of Nrf2, SLC7A11, GPX4, ACSL4, and TFR1 proteins in pulmonary tissues were also evaluated. Results All rats in the sham group survived.
The survival rates in the low-dose (SL), medium-dose (SM), and high-dose (SH) groups (60.0%, 73.3%, and 86.7%, respectively) were higher than those in the CLP group (53.3%), although the differences were not statistically significant.